Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase
- PMID: 18989752
- DOI: 10.1007/s11033-008-9392-3
Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase
Abstract
Morquio A is an autosomal recessive disease caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leading to the lysosomal accumulation of keratan-sulfate and chondroitin-6-sulfate. We evaluated in HEK293 cells the effect of the cytomegalovirus immediate early enhancer/promoter (CMV) or the elongation factor 1alpha (EF1alpha) promoters, and the coexpression with the sulfatase modifying factor 1 (SUMF1) on GALNS activity. Four days postransfection GALNS activity in transfected cells with CMV-pIRES-GALNS reached a plateau, whereas in cells transfected with EF1alpha-pIRES-GALNS continued to increase until day 8. Co-transfection with pCXN-SUMF1 showed an increment up to 2.6-fold in GALNS activity. Finally, computational analysis of transcription factor binding-sites and CpG islands showed that EF1alpha promoter has long CpG islands and high-density binding-sites for Sp1 compared to CMV. These results show the advantage of the SUMF1 coexpression on GALNS activity and indicate a considerable effect on the expression stability using EF1alpha promoter compared to CMV.
Similar articles
-
Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris.Sci Rep. 2016 Jul 5;6:29329. doi: 10.1038/srep29329. Sci Rep. 2016. PMID: 27378276 Free PMC article.
-
Adeno-associated virus gene transfer in Morquio A disease - effect of promoters and sulfatase-modifying factor 1.FEBS J. 2010 Sep;277(17):3608-19. doi: 10.1111/j.1742-4658.2010.07769.x. FEBS J. 2010. PMID: 20716181
-
Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins.Mol Genet Metab. 2007 Jul;91(3):251-8. doi: 10.1016/j.ymgme.2007.02.009. Epub 2007 May 10. Mol Genet Metab. 2007. PMID: 17498992
-
Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.Mol Genet Metab. 2013 Sep-Oct;110(1-2):54-64. doi: 10.1016/j.ymgme.2013.04.002. Epub 2013 Apr 10. Mol Genet Metab. 2013. PMID: 23665161 Free PMC article. Review.
-
Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database.Hum Mutat. 2014 Nov;35(11):1271-9. doi: 10.1002/humu.22635. Epub 2014 Sep 17. Hum Mutat. 2014. PMID: 25137622 Free PMC article. Review.
Cited by
-
Morquio A syndrome: diagnosis and current and future therapies.Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1(0 1):141-51. Pediatr Endocrinol Rev. 2014. PMID: 25345096 Free PMC article. Review.
-
Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris.Sci Rep. 2016 Jul 5;6:29329. doi: 10.1038/srep29329. Sci Rep. 2016. PMID: 27378276 Free PMC article.
-
Therapies of mucopolysaccharidosis IVA (Morquio A syndrome).Expert Opin Orphan Drugs. 2013 Oct 1;1(10):805-818. doi: 10.1517/21678707.2013.846853. Expert Opin Orphan Drugs. 2013. PMID: 25419501 Free PMC article.
-
Assessment of different promoters in lentiviral vectors for expression of the N-acetyl-galactosamine-6-sulfate sulfatase gene.J Hum Genet. 2025 Jun 10. doi: 10.1038/s10038-025-01353-x. Online ahead of print. J Hum Genet. 2025. PMID: 40494905
-
Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles.Sci Rep. 2022 Sep 3;12(1):15045. doi: 10.1038/s41598-022-19407-x. Sci Rep. 2022. PMID: 36057729 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources